Hope they take over the pain division
Apr 17, 2015
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) 2%
DUBLIN, IRELAND -- (Marketwired) -- 04/17/15 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs today announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/596,813, entitled "Diclofenac Topical Formulation" that covers Horizon's U.S. approved product PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%).
"This Notice of Allowance furthers our goal of strengthening the PENNSAID 2% patent estate and supports the innovation behind this important medicine for patients in need of treatment," said Timothy P. Walbert, chairman, president and chief executive office, Horizon Pharma plc.
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire in 2027. After issuance, Horizon plans to list the patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the eighth U.S. patent to be listed in the Orange Book for PENNSAID 2%.
About PENNSAID® 2%
PENNSAID (diclofenac sodium topical solution) 2% w/w is a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain of osteoarthritis (OA) of the knee(s). PENNSAID contains diclofenac sodium, an NSAID, and also includes dimethyl sulfoxide (DMSO), a powerful penetrating agent that helps ensure that diclofenac sodium is absorbed through the skin to the site of inflammation and pain. PENNSAID 2% is an alternative to oral NSAID treatment, reducing systemic exposure to a fraction of that provided by the oral NSAID diclofenac. The only topical NSAID offered with the convenience of a metered-dose pump, PENNSAID 2% is applied in two pumps, twice daily to the site of OA knee pain. For more information, please see www.PENNSAID.com.